January 05, 2024

Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 04, 2024

Agenus to Participate in B. Riley Healthcare Conference

December 20, 2023

Botensilimab/Balstilimab Data in Neoadjuvant Colorectal Cancer Selected for ASCO-GI 2024

December 11, 2023

Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific Program

November 07, 2023

Agenus Reports Third Quarter 2023 Results

October 26, 2023

Agenus to Provide Third Quarter 2023 Financial Report and Corporate Update

October 22, 2023

Agenus Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma

October 21, 2023

ESMO 2023: Agenus’ Botensilimab/Balstilimab Combination Delivers Durable Responses across Multiple Sarcoma Subtypes

October 10, 2023

Agenus Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal Cancer

October 05, 2023

Agenus To Host BOT/BAL Program Update at ESMO 2023

September 01, 2023

Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 28, 2023

Agenus to Participate in September Investor Conferences

August 23, 2023

Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers

August 09, 2023

SaponiQx Announces Breakthrough in Scaling Up of STIMULON™ Cultured Plant Cell Adjuvant

August 08, 2023

Agenus Reports Second Quarter 2023 Results

July 28, 2023

Agenus Botensilimab/Balstilimab Data Update in Sarcomas Selected for Oral Presentation at ESMO 2023

July 26, 2023

Agenus to Provide Second Quarter 2023 Financial Report and Corporate Update

July 20, 2023

Agenus Expands Executive Leadership Team

June 30, 2023

ESMO GI Data: Agenus' Botensilimab/Balstilimab Combination Achieves Unprecedented Survival in Advanced Colorectal Cancer

June 05, 2023

Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO

June 05, 2023

Agenus Announces Virtual Annual Shareholders Meeting

May 25, 2023

Agenus to Participate in Jefferies Healthcare Conference

May 09, 2023

Agenus Provides Corporate Update and First Quarter 2023 Financial Results

May 03, 2023

Agenus Selected for Late-Breaking Oral Presentation at ESMO-GI

April 26, 2023

Agenus to Present at the American Society of Clinical Oncology 2023 Annual Meeting

April 25, 2023

Agenus to Provide Corporate Update and First Quarter 2023 Financial Report

April 24, 2023

Agenus to Participate in May Investor Conferences

April 17, 2023

Agenus Receives Fast Track Designation for Botensilimab and Balstilimab in Colorectal Cancer

March 30, 2023

Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics

March 27, 2023

Agenus’ Botensilimab in Combination with Balstilimab Shows 33% Durable Responses in Ovarian Cancer

March 14, 2023

Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives

March 12, 2023

Agenus Cancels Conference Call to Discuss the Company’s Minority Cash Holdings at SVB in Light of Government’s SVB Deposit Access Announcement

March 11, 2023

Agenus Schedules Conference Call to Discuss the Company’s Minority Cash Holdings at SVB

February 28, 2023

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2022 Financial Report

February 28, 2023

Agenus to Present Botensilimab Data in Oral Plenary Session at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer

January 26, 2023

Agenus to Participate in February Investor Conferences

January 23, 2023

Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

January 10, 2023

Agenus to Participate at B Riley Securities’ 2023 Virtual Oncology Conference

December 21, 2022

Agenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GI

November 17, 2022

Agenus Data at CTOS 2022 Highlight Durable Clinical Responses of Botensilimab / Balstilimab Combination in Advanced Sarcoma

November 16, 2022

Agenus to Participate at 5th Annual Evercore ISI HealthCONx Conference

November 14, 2022

Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers

November 08, 2022

Agenus Provides Corporate Update and Third Quarter 2022 Financial Report

October 25, 2022

Agenus to Provide Corporate Update and Third Quarter 2022 Financial Report

October 13, 2022

GSK’s older adult RSV vaccine candidate, containing Agenus’ QS-21 STIMULON™, shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial

October 05, 2022

Agenus to Host “The Road Taken” R&D Event on November 12, 2022

October 05, 2022

Agenus to Present Botensilimab Data at a Plenary Session of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

September 12, 2022

Agenus Initiates Botensilimab Phase 2 ACTIVATE Trials in Advanced MSS Colorectal Cancer and Advanced Melanoma

September 12, 2022

Agenus Makes Senior Regulatory and Clinical Appointments

August 09, 2022

Agenus Provides Corporate Update and Second Quarter 2022 Financial Report